For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and Attruby represents a true advancement . These novel therapies stabilize the transthyretin protein, preventing its harmful build-up and lessening the burden of the disease . Patients are now reporting positive outcomes in